New Alzheimer's drug shows promise in early trial
Disease control
Completed
This study tested a new drug called 50561 in 68 people with mild to moderate Alzheimer's disease. Participants received either a high dose, low dose, or a placebo. The main goal was to see if the drug could slow down cognitive decline over 24 weeks using a standard memory and thi…
Phase: PHASE2 • Sponsor: Beijing Joekai Biotechnology LLC • Aim: Disease control
Last updated Jun 26, 2026 18:31 UTC